LLY Quote, Financials, Valuation and Earnings

Biogen has a net margin of 8.48% compared to Eli Lilly and's net margin of 15.76%. Eli Lilly and's return on equity of 66.4% beat Biogen's return on equity of 10.52%.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 23.68%. On the other hand Biogen has an analysts' consensus of $242.83 which suggests that it could grow by 62.95%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.409, which suggesting that the stock is 59.07% less volatile than S&P 500. In comparison Biogen has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.074%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.65%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Biogen quarterly revenues of $2.5B. Eli Lilly and's net income of $970.3M is higher than Biogen's net income of $388.5M. Notably, Eli Lilly and's price-to-earnings ratio is 86.02x while Biogen's PE ratio is 13.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.61x versus 2.26x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 8.48% compared to Eli Lilly and's net margin of 0.7%. Eli Lilly and's return on equity of 66.4% beat Moderna's return on equity of -17.44%.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 23.68%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.23%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.409, which suggesting that the stock is 59.07% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.65%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Moderna quarterly revenues of $1.9B. Eli Lilly and's net income of $970.3M is higher than Moderna's net income of $13M. Notably, Eli Lilly and's price-to-earnings ratio is 86.02x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.61x versus 3.08x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 8.48% compared to Eli Lilly and's net margin of 36.03%. Eli Lilly and's return on equity of 66.4% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 23.68%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.39%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.409, which suggesting that the stock is 59.07% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.65%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Eli Lilly and's net income of $970.3M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Eli Lilly and's price-to-earnings ratio is 86.02x while Regeneron Pharmaceuticals's PE ratio is 17.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.61x versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 8.48% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 66.4% beat Viking Therapeutics's return on equity of --.

Eli Lilly and has a consensus price target of $984.05, signalling upside risk potential of 23.68%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 159.74%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.409, which suggesting that the stock is 59.07% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.65%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $970.3M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Eli Lilly and's price-to-earnings ratio is 86.02x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.61x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.